Genome editing technique enables partial inhibition of gene function in crops
Researchers at Kumamoto University have successfully executed a practical trial of a new genome-editing technique that allows ...
KSAL1d
Geneticist Outlines Promise of Cattle Gene Editing
Gene editing has taken root in plant breeding, leading to numerous advances in plant-based foods. K-State scientists, for ...
BioPharma Dive2d
Beam base editing therapy gets ‘proof of concept’ in rare lung disease
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
Interesting Engineering on MSN7d
Genetic testing paves way for juicier, larger tomatoes and eggplants
The genetic duplicates, or paralogs, played a crucial role in shaping traits such as flowering time, fruit size, and shape.
Hub1d
Scientists design experimental protein booster for rare genetic diseases
Johns Hopkins scientists develop mRNA "booster" as potential new way to treat rare genetic diseases marked by too low levels ...
BioSpace2d
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
MIT Technology Review8d
De-extinction scientists say these gene-edited ‘woolly mice’ are a step toward woolly mammoths
The animals, the first to have been created by Colossal Biosciences, have fluffy coats and curly whiskers.
ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI
ElevateBio will leverage artificial intelligence to expand and accelerate CRISPR discovery, design, and drug development for thousands of complex ...
pharmaphorum3d
Beam launches $500m financing on base-editing trial data
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...
GEN - Genetic Engineering and Biotechnology News2d
In Vivo Base Editing Gets Boost with Positive Initial Data Announced by Beam Therapeutics
Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).